Literature DB >> 17716796

The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma.

Qian Bian1, Takahiro Kato, Akira Monji, Sadayuki Hashioka, Yoshito Mizoguchi, Hideki Horikawa, Shigenobu Kanba.   

Abstract

An accumulating body of evidences point to the significance of neuroinflammation and immunogenetics in schizophrenia, characterized by increased serum concentration of several pro-inflammatory cytokines. In the central nervous system (CNS), the microglial cells are the major immunocompetent cells which release pro-inflammatory cytokines, nitric oxide (NO) and reactive oxygen species to mediate the inflammatory process. In the present study, we investigated whether or not atypical antipsychotics, namely perospirone, quetiapine and ziprasidone, would have anti-inflammatory effects on the activated microglia which may potentiate neuroprotection. All three atypical antipsychotics significantly inhibited NO generation from activated microglia while perospirone and quetiapine significantly inhibited the TNF-alpha release from activated microglia. Antipsychotics, especially perospirone and quetiapine may have an anti-inflammatory effect via the inhibition of microglial activation, which is not only directly toxic to neurons but also has an inhibitory effect on neurogenesis and oligodendrogenesis, both of which have been reported to play a crucial role in the pathology of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17716796     DOI: 10.1016/j.pnpbp.2007.06.031

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  41 in total

Review 1.  Inflammation in Mental Disorders: Is the Microbiota the Missing Link?

Authors:  Sophie Ouabbou; Ying He; Keith Butler; Ming Tsuang
Journal:  Neurosci Bull       Date:  2020-06-27       Impact factor: 5.203

2.  Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [(11)C]PBR28 PET Brain Imaging Study.

Authors:  Peter S Bloomfield; Sudhakar Selvaraj; Vincenzo de Paola; Oliver D Howes; Mattia Veronese; Gaia Rizzo; Alessandra Bertoldo; David R Owen; Michael Ap Bloomfield; Ilaria Bonoldi; Nicola Kalk; Federico Turkheimer; Philip McGuire
Journal:  Am J Psychiatry       Date:  2015-10-16       Impact factor: 18.112

3.  Acute Psychosis in an Adolescent Treated With Infliximab for Crohn's Disease.

Authors:  Michael R Locher; Abdulkader Alam
Journal:  Prim Care Companion CNS Disord       Date:  2015-06-30

4.  Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment.

Authors:  Ida S Haussleiter; Martin Brüne; Georg Juckel
Journal:  Ther Adv Neurol Disord       Date:  2009-01       Impact factor: 6.570

5.  Moving past the "neuroncentric" perspective: a role for glia in neuropsychiatric disorders.

Authors:  Aaron Y Lai; Kamaldeep S Dhami; Kathryn G Todd
Journal:  J Psychiatry Neurosci       Date:  2009-05       Impact factor: 6.186

Review 6.  Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?

Authors:  Robert K McNamara; Francis E Lotrich
Journal:  Expert Rev Neurother       Date:  2012-09       Impact factor: 4.618

7.  Schizophrenia-like disorder associated with etanercept treatment.

Authors:  Onome Victor Atigari; David Healy
Journal:  BMJ Case Rep       Date:  2014-01-13

Review 8.  The neurotrophic and neuroprotective effects of psychotropic agents.

Authors:  Joshua Hunsberger; Daniel R Austin; Ioline D Henter; Guang Chen
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

9.  Oligodendroglial alterations and the role of microglia in white matter injury: relevance to schizophrenia.

Authors:  Li-Jin Chew; Paolo Fusar-Poli; Thomas Schmitz
Journal:  Dev Neurosci       Date:  2013-02-27       Impact factor: 2.984

Review 10.  Inflammatory Cytokines and Antipsychotic-Induced Weight Gain: Review and Clinical Implications.

Authors:  Trehani M Fonseka; Daniel J Müller; Sidney H Kennedy
Journal:  Mol Neuropsychiatry       Date:  2016-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.